|
|
Can Pathway-Based Approaches Overcome the Problems of Target-Based Drug Discovery?Published by: Decision Resources Published: Jun. 12, 2006 - 22 Pages Table of Contents
AbstractAfter the human genome was sequenced, pharmaceutical and biotechnology companies hoped that their enormous investment in drug discovery and development programs—$51.3 billion in 2005—would yield higher R&D productivity. However, the industry’s target-based research approach has failed to generate many drugs that work via novel mechanisms of action, and drugs that fail late in clinical trials significantly drive up the overall cost of drug development. Companies are now reevaluating their drug discovery research strategies, implementing or considering a shift to a pathwaybased approach in the hopes of unlocking the promise of genomics-based drug discovery. By studying the routes by which drugs act on a system (i.e., a signaling pathway or network) rather than simply scrutinizing a specific target, companies hope to better understand how a disease progresses, which they hope will in turn lead to better-designed and more effective therapeutic strategies.In this report, we discuss recent progress in pathway-based drug discovery. We review studies aimed at expanding researchers’ knowledge of key pathways and those that use whole-pathway screening methods. We also highlight the application of pathwaybased methods to drug discovery and translational medicine and discuss the impact of pathway-based strategies on pharmaceutical R&D. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||